Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air is currently in a transitional period as it undergoes a leadership change, with the appointment of Robert Goodman as CEO. This transition signals a focus on commercialization and revenue growth, as evidenced by the company's reported fiscal 3Q26 revenue of $2.2M. Additionally, the company's recent interim data for its Beyond Cancer segment showed encouraging results, with potential for the NeuroNOS asset to generate value in the future.

Bears say

Beyond Air is facing multiple risks, including financial and capital risks, commercialization risks, and clinical development risks. The company's dependence on third-party partnerships and its reliance on its intellectual property also pose potential challenges. While it has achieved approval for its primary commercial product, the LungFit PH system, its optional asset, the NeuroNOS platform, may not generate significant revenue in the near future. Management should focus on expanding hospital adoption and pursuing other pulmonary indications to mitigate these risks.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.